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Abstract 
 
Background: Loss of muscle mass, strength and/or function are common in the increasing 
elderly population. A conceptual and diagnostic term often used for these age related 
alterations of muscle mass is sarcopenia. Strategies to maintain functional ability and health 
are therefore of interest. Using dietary supplements, essential amino acids have shown 
promise to prevent this muscle wasting. 
 
Aim: To evaluate currently published data investigating the use of essential amino acids in 
prevention of age related muscle loss in individuals with or at risk of sarcopenia over the age 
of 65. Outcomes will be lean body mass, strength and functional tests. 
 
Methods: The electronic databases PubMed and Scopus were searched. Inclusion criteria 
were experimental studies in English from 1994-2015, using essential amino acid 
supplementation and subjects above 65 years. Search terms conducted were “essential amino 
acids” and “sarcopenia”. A manual search for studies in found articles was also performed. 
 
Results: Eight studies meeting the predetermined inclusion criteria were analyzed. The 
studies all indicated that intake of essential amino acids could maintain or increase lean body 
mass and muscle strength/function. The highest effect was seen in those subjects with 
sarcopenia. 
 
Conclusions: Supplementation with essential amino acids seem to be effective in individuals 
above 65 years of age with low muscle mass, low strength or impaired function for 
maintenance or increased lean body mass and muscle strength/function. Optimal dose, 
intervention period and adequate combination of amino acids remain to be determined  
 
Keywords: Essential amino acids, sarcopenia, leucine. 
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Abbreviations 
 
1RM  One-repetition max 
25OHD 25-hydroxy-vitamin D 
AA Amino acids 
ADL Activities of daily life 
BIA Bioelectrical impedance analysis 
BMI Body mass index 
COPD Chronic obstructive pulmonary disease 
DXA  Dual-energy X-ray absorptiometry  
EAA Essential amino acids 
EFSA European food safety authority 
DHEA Dehydroepiandrosterone 
GH Growth Hormone  
HMB Beta-Hydroxy beta-methylbutyric acid 
IGF-1 Insulin-like growth factor 1 
LBM Lean body mass 
Leu Leucine 
MIMS  Maximal isometric muscle strength 
RCT  Randomized controlled trial 
SD Standard deviation 
SMI Skeletal muscle mass index  
SPPB Short physical performance battery 
VDR intracellular vitamin D receptor 
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Introduction 
 
Background 
 
With an increasing elderly population, conditions that deteriorate the health of those of old 
age will become more prevalent (1). The progressive loss of muscle mass and muscle function 
lowers mobility and quality of life (2). The current conceptual and diagnostic definition of this 
condition is sarcopenia. It is a syndrome characterized by progressive and generalized loss of 
skeletal muscle mass and strength. Old age is considered as the primary cause if no other 
specific cause or disorder can be found (2).  
 
Sarcopenia leads to varying degrees of immobility and loss in quality of life (1). From the 
fifth decade there is a loss of 1-2 % of lean body mass per decade and after the age of 60 there 
is potentially a 3 % loss of muscle strength per decade. It is estimated that 5-13% of people 
aged 60-70 are affected by sarcopenia and 11-50% affected above the age of 80 (3). When in 
2015 comparing different definitions of sarcopenia in 308 elderly (mean age 81) individuals 
the prevalence varied between 0-15% in healthy individuals and 2-34% in geriatric 
outpatients (4). Worth noting is that the relationship between muscle mass and muscle 
strength is not linear (5). Thus an evaluation of muscle function is often as important.  
 
This study is a systematic review intending to evaluate the effect of an EAA supplement on 
muscle mass, strength and function in individuals over the age of 65. Muscle wasting is 
common in individuals above the age of 65, so this age was used as a cut-off (3). Since 
sarcopenia is not yet a universally accepted and used diagnosis, articles with subjects fitting 
the chosen inclusion criteria but not diagnosed with sarcopenia is included in the analysis of 
data.. The subjects analyzed in the studies that are not diagnosed are referred to as at risk of 
sarcopenia.  
 
Sarcopenia definition and diagnosis 
 
There are currently three different definitions in wider use, a problem when aiming to design 
studies, diagnose and evaluate treatments (1, 6, 7). The diagnosis of sarcopenia currently in 
the widest use in Europe is defined in the 2010 report “Sarcopenia: European consensus on 
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definition and diagnosis” (1). In summary the definition is having low muscle mass and one 
or both conditions of low muscle strength or poor physical performance (detailed methods 
and cut-off points for the diagnosis based on body mass index (BMI) is explained in the 
article). For measurement of muscle mass the preferred method is Dual-energy X-ray 
absorptiometry (DXA) and the cut-off point is a skeletal muscle mass index (SMI) 2 standard 
deviations (SD) below the mean of young adults of the same gender. For measurement of 
muscle strength a preferred method is measuring handgrip strength and <30kg for males and 
<20kg for females is a cut-off point. Performance could be measured using short physical 
performance battery test (SPPB) which tests balance, gait speed and chair stand. Each test is 
graded 0-4 with 4 being the highest. So 10-12 is considered high performance. The cut-off 
score for the diagnostic criteria is <8 for both genders. Even though different definitions on 
the diagnoses exist, they share many similarities and international working groups are at the 
moment trying to create a universal definition. 
 
Pathophysiology 
 
Sarcopenia is a multifactorial condition with 
multiple potential underlying mechanisms (8) 
(as illustrated in Figure 1). The primary cause 
is age related and behavioral e.g. a more 
sedentary life style, decreasing energy intake 
and age related physiological changes such as 
altered sensitivity and synthesis of anabolic 
hormone and impaired protein metabolism (2). 
Both these factors contribute to lowering the general 
nutrition intake, especially the dietary protein intake and its quality (1).  
 
A decreased level of growth hormone/insulin-like growth factor 1 (GH/IGF1) is often seen in 
parallel to changes in body composition with increased visceral fat mass and decreased lean 
body mass (LBM) (9). Of all the hormonal pathways the cortisol-GH axis has been proposed 
as the most influential factor for changes in body composition (10).  
 
Low grade inflammation is associated with a variety of conditions such as insulin resistance, 
osteoporosis and reduced protein synthesis (2). Loss of LBM including muscle mass 
Adapted from A.J. Cruz-Jentoft et al 2010 (1) 
 
 
Figure 1. Mechanisms of sarcopenia. 
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according to ageing does not necessarily imply weight loss, suggesting that a corresponding 
accumulation of body fat occurs (11). Abdominal fat accumulation is in itself associated with 
low grade inflammation caused by higher levels of circulating pro-inflammatory cytokines as 
TNF, IL1 and IL6 (2). This may negatively affect protein synthesis and metabolism.  
 
The quality and quantity of protein intake is also a contributor to muscle wasting. The 
recommended intake for the general population is 0.8 g protein/kg body weight/day and the 
European food safety authority (EFSA) published in 2011 a report on their scientific opinion 
on daily protein intake. They found that the daily protein intake in elderly 65 years + in the 
United Kingdom for males was mean 71.5 g (SD 17.0 g) and for females mean 56.0 g (SD 
13.4 g). Most European countries had comparable protein intake levels (12). An American 
study observing 2066 subjects aged 70-79 showed that about 40 % did not even meet the 
minimum 0.8 g protein/kg body weight/day in intake (13).  
 
A higher protein intake might be motivated since it is connected to an impaired response of 
protein metabolism to nutrition (14). This phenomena could partly be attributed to that is 
seems elderly have an altered function of specific amino acid (AA) transporters (15). This 
mechanism could explain some of their dietary AA resistance. A study compared the 
accretion of muscle protein in healthy elderly compared to healthy young subjects. The 
protein uptake was less in the elderly suggesting that a higher dose is needed for optimal 
protein synthesis (16). Impaired protein metabolism seem to be age related even though the 
physiological mechanisms is poorly understood.  Forced inactivity such as in hospitalization 
leads to loss of muscle mass (17). This is an increased risk for loss of function in the elderly. 
One study illustrate that inactivity in itself impair different anabolic signaling pathways, 
especially mTORC1. This effect is more significant  in older individuals compared to younger 
(18). Hence inactivity and old age in itself may blunt the anabolic stimulation of EAA. 
 
As shown, the protein intake in elderly is often insufficient. Low protein intake in 
combination with other factors mentioned such as impaired protein metabolism and sensitivity 
might be justify to increase the recommended intake. A position paper from the PROT-AGE 
study group recommends 1.2g protein/kg body weight/day to maintain or regain lean body 
mass (19). Another report from 2008 even suggest the optimal intake for elderly might be as 
high as 1.5g protein/kg body weight/day (20). A level that could be difficult to reach by 
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normal food intake in frail or sick older adults, illustrating the need for a different approach to 
reach adequate intake. En excess protein intake might also have negative consequences. There 
is potential risks with bones mineral loss and negative impact on renal function (21). 
 
These factor mentioned highlights the complicated and multifactorial mechanisms of 
sarcopenia, both intrinsic changes in the muscles, general changes such as inflammation, 
impaired metabolism and lifestyle/behavioral factors contribute to the condition.  
 
Current potential treatments  
 
There are several diverse suggested treatment approaches to different mechanisms (3). Some 
results have been obtained with resistance training, hormonal treatment, metabolic treatments 
such as vitamin D and nutritional interventions such as high caloric supplements and essential 
amino acids (22).  
 
Resistance training in combination with nutrition has been shown beneficial for muscle 
synthesis (23, 24). However many older adults suffer from physical disabilities and 
hospitalizations may lead to forced inactivity. Physical therapy is not always an option and 
other effective treatment methods to ameliorate muscle loss while inactive is needed. Since 
peak muscle mass is often achieved earlier in life, effort to prevent sarcopenia trough diet and 
nutrition throughout the individuals lifetime might be a key to achieve physical capability in 
old age (25). 
 
Hormonal treatment attempts with growth hormone (GH) has been tried, but no increased 
muscle strength was found in elderly (26). Administering GH does increase LBM but was 
also associated with adverse effects, mainly diabetes and glucose intolerance (27). A review 
from 2007 on GH administration to healthy elderly concluded that GH did show a small effect 
on LBM but increased to rate of adverse events to much to be recommended as a potential 
therapy (28). A study conducted on testosterone for men and dehydroepiandrosterone 
(DHEA) for women concluded: “Neither DHEA nor low-dose testosterone replacement in 
elderly people has physiologically relevant beneficial effects on body composition, physical 
performance, insulin sensitivity, or quality of life” (29). 
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25-hydroxy-vitamin D (25OHD) is a vitamin as well as a pro-hormone obtained through diet 
and synthesized by the skin from the exposure of ultraviolet light. It primarily promotes bone 
resorption and intestinal calcium absorption, increasing serum calcium concentration. But it 
also seem to have  other effects through the intracellular vitamin D receptor (VDR) that has 
been found in both cardiac and muscle cells (30). Its association to sarcopenia was examined 
in a prospective study from 2010 (31). 686 community dwelling elderly individuals were 
followed for a mean of 2.6 ± 0,4 years. Serum levels of 25OHD were repeatedly measured 
using immunoassays and their sun exposure was measured using questionnaires. Muscle mass 
and muscle strength were measured using DXA and strength dynamometers. The study 
showed that serum 25OHD concentrations ≥50 nm were associated with a higher muscle mass 
and muscle function. However since this was a prospective study and not a controlled trial 
there is a lot of methodological limitations and unexplored confounding factors. 
 
Omega-3 fatty acids are polyunsaturated fatty acids. They cannot be synthesized by the body 
and has to be supplied through the diet. Omega-3 acids contribute to normal metabolism 
through several different pathways. Though supplementation does not appear to decrease all-
cause mortality on a population based level (32). Its suggested positive anabolic effect was 
reviewed in a study from 2014 (33) and even thou the mechanism is not fully understood 
Omega-3 seem to lower the elderly’s anabolic resistance to AA. Th area should be explored 
further and maybe Omega-3 could potentially be administered in conjunction with AA to 
increase the anabolic response.  
 
Other pharmacological strategies besides hormones treatments have not yet been developed. 
But an observational study from 2002 showed that elderly subject treated with angiotensin 
converting inhibitors a clear reduction in the decline in muscle strength was observed 
compared to other anti-hypertensive agents (34). Thus there seem to be a possible future 
potential to combine nutritional and pharmacological approaches in prevention and treatment.  
 
Essential amino acids 
 
Protein supplements alone do not show a positive effect on LBM compared placebo in a 
diverse elderly population, according to a meta-analysis (35). The efficiency of essential 
amino acids (EAA) for protein synthesis is more than twice that of whey protein on a g/g 
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basis (36). EAA has a great advantage compared to other protein supplementation since it 
increases the protein synthesis significantly more per calorie consumed. This Results in less 
satiety, an important factor in the elderly who already struggle to consume enough calories. A 
systematic review and meta-analysis of leucine (Leu), and EAA concluded that is suggested 
that “Leu supplementation is useful to address the age-related decline in muscle mass in 
elderly individuals, as it increases the muscle protein fractional synthetic rate” (37). Showing 
the potential of EAA supplementation in promoting protein synthesis and thus aid in 
maintaining or regaining lean body mass in elderly.  
 
Research question 
 
Can EAA supplementation maintain or increase LBM, strength and function in elderly 
individuals (≥65 years) with or at risk of sarcopenia. 
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Methods 
 
Inclusion & exclusion criteria 
 
Searches were conducted in PubMed and Scopus databases. Selected studies were limited to 
those in the English language with a 20-year span ranging from 1994-2014. Search terms 
conducted for all three databases were “essential amino acids sarcopenia”. A manual search 
for studies in each selected studies and earlier systematic reviews found from this search was 
also done.  Only studies eligible according to the inclusion and exclusion criteria were 
included. The searches were conducted in January 2015.  
 
Table 1. Inclusion & exclusion criteria 
Inclusion criteria Exclusion criteria 
English language In-vitro studies 
Published studies, year span 1994-2014 Case reports 
Experimental studies Review articles 
Clinical subjects, age >65 years Observational studies 
EAA supplementation  
Full texts found  
 
 
Study Selection 
 
One person conducted the searches 
and the studies were selected 
according to the inclusion and 
exclusion criteria.  
 
Of the 134 studies screened 125 were 
excluded for not being eligible 
according to the inclusion/exclusion 
criteria. One study fitted all the initial 
criteria but was excluded from the 
final analysis since a full text was not 
obtained. It was a study by 
Figure 2. Flow chart 
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Scognamilio et al 2004 (38). In accordance to the research question and the inclusion & 
exclusion criteria studies with subject both diagnosed and not diagnosed with sarcopenia were 
included. Figure 2 shows a flowchart for this study selection process. 
 
Quality assessment of studies 
 
Quality analysis and grading of studies were performed according to suggested guidelines 
defined in the GRADE system. Review templates were acquired from HTA-centrum from the 
Sahlgrenska Academy (39). According to GRADE, there are three different grades of 
evidence when grading the quality of the studies: low, moderate and high. Further, there are 
four different grades when grading the evidence strength of chosen endpoints: very low, low, 
moderate and high. 
 
Endpoints analyzed were LBM, muscle strength and muscle function. Muscle function is of 
crucial importance for the elderly in the ability of managing basic needs in an everyday life. 
There is no universal definition of muscle function. Effects chosen in the present studies were 
mostly MIMS hand dynamometers and different walking tests. Both functions have a large 
impact on autonomy and the overall quality of life. 
 
Ethics 
 
This systematic review is based on earlier published work and therefore was ethical 
establishment not necessary. All individual articles in this review had ethical approval. 
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Results 
 
Study descriptions from eight studies are summarized in table 2 spanning from 2005 to 2012 
(40-47). The intervention results are summarized in table 3. 
 
Study characteristics 
 
The studies involved a total of 454 subjects (273 female, 140 male, 41 subjects in one study 
had not their gender specified). The aim was to examine studies with subjects 65 years and 
older. In one study the inclusion age was >40 years (41). However, with mean age presented 
as 75 ± 7, most subjects were ≥65 years and therefore the study was included in this review. 
All analyzed studies were clinical trials, six were RCTs, one study had only one intervention 
group and one was an open label cross-over study.  
 
They all had different study protocols and used somewhat different variables, such as blood 
lactate, glucose, cytokines etc. Most of these were considered not relevant for this systematic 
review. The most relevant variables for the present study were LBM and muscle 
function/strength. LBM was measured using DXA except in the two Dal Negro et al studies 
that used bioelectrical impedance analysis (BIA). Strength/function was measured using 
different functional methods in the studies.  
 
Scognamiglio et al 2005 
The aim of this study was to assess the effect of 12g/day oral EEA supplementation on muscle 
strength and muscle function. 100 eldery subjects ( > 65 years) with reduced physical capacity 
were randomized non blinded into either the EAA group or a placebo group for 3 months. The 
authors did not look at lean body mass but evaluated muscle strength using a MIMS hand 
dynamometer and function was evaluated using standardized walking tests. 
 
All measured outcomes improved compared to baseline in the EAA group but not the placebo 
group. The improvements in ambulatory capacity and handgrip strength were greater. This 
can partly be explained by the fact that the subjects were encountered in everyday practice 
during the study. Even though subjects in intervention group and placebo group participated 
in the same exercise routine, the large increase was seen only in the intervention group.  
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Børsheim et al 2008 
The aim of this study was to determine if a regular intake of EAA would improve LBM and 
muscle function in elderly glucose intolerant subjects (defined as a plasma glucose 
concentration >180 mg/dl at 1 h or >140 mg/dl at 2 h after oral intake of 75 g glucose). The 
authors of the study reasoned that since insulin resistance is common in the elderly population 
they wanted the subjects to have the same insulin sensitivity so the positive interaction 
between insulin and AA would result in a difference in anabolic response. 
 
This was an intervention study with only one intervention group. 12 subjects were included 
(67.0 ±5.6 SD years, 7 females, 5 males) and they ingested 11g EAA + arginine for 16 weeks. 
They were outpatients and their regular diet or activity was not modified. The subjects 
underwent a full body DXA at week 0, 4, 8, 12, and 16 to determine LBM. Muscle strength 
and function was determined with 1RM max tests in weight machines and different functional 
tests such as walking speed, timed floor transfer and static balance test.  
 
After 16 weeks there was a significant improvement in LBM, muscle strength and most of the 
physical muscle function tests. This occurred despite no other changes in physical activity or 
dietary changes.  
 
The study did not include a placebo group. The authors assumed that no improvement would 
occur in the subjects without the intervention based on. Subjects’ baseline values were used as 
a control for comparison.  
 
Solerte et al 2008 
The aim of this study was to examine the effect of orally administered EAA in elderly 
subjects (age range 66–84 years) with reduced LBM and diagnosed with sarcopenia. Subjects 
were outpatients living independently. The protocol was a randomized open-label crossover 
with 41 subjects, no information were given on the gender. Main outcome was lean body 
mass which was measured using a DXA and the intervention consisted of 16g EAA (8g 
morning and evening) daily.  
 
This cross-over study had different phases. First a run in period of 30 days and then the 
baseline values was established. The subjects were then divided into 2 groups. One received 
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placebo and the other the EAA intervention for 4 months. Once this was done both groups had 
a 15 day washout period and then the groups switched who got the placebo and who got the 
EAA for 4 months again. After the crossover periods both groups received EAA for 8 months, 
something the authors call a “maintenance period”. The parameters (except LBM) were 
examined at baseline and after 4, 6, 8, and 16 months. The result does support the assumption 
that the gain of using EAA supplementation is greatest the first months and then stabilizes. 
 
This study lacked both information about the gender and the LBM results of the intervention 
compared to placebo during the different study periods. So the results impact on this review 
was unfortunately limited. 
 
Dillon et al 2009 
The aim of this study was to examine if EAA supplementation improves LBM, maximum 
muscle strength, and the metabolic outcomes muscle protein fractional synthesis rate and the 
IGF-I muscle protein receptor expression. It was a double-blind RCT with 7 elderly (68 ± 2 
years) women in each group. They were all living autonomously at home. One group received 
placebo and the other 15g EAA daily. The intervention spanned 3 months with one 
measurement day 1 and at the end of the study period. Subjects collected their capsules once a 
month. LBM was measured using DXA. Muscle strength was assessed using One-repetition 
max (1RM) in traditional weight machines. Different metabolic outcomes were not included 
in the result of this review. 
 
The results was that the ingestion of EAA increased LBM 3,9 % in the intervention group but 
in the placebo group they only increased 0,7 %. Strength remained unchanged in both group 
so they were not statistically significant and the final data was not shown.   
 
Ferrando et al 2009 
Since prolonged inactivity is common in hospitalization the aim of this study was to evaluate 
the effect of EAA supplementation in elderly (mean 68 ± 5 years) that was subject to a 10 day 
bed rest protocol. The subjects were divided into two groups with 11 subjects in each group 
completing the study. They were given either a placebo or 15 g of EAA three times a day 
during the bed rest period. LBM and different tests of muscle function/strength was chosen as 
end points. As seen in table 3 both groups lost LBM and muscle strength but the EAA group 
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lost significantly less. Methods used in measuring were muscle protein synthesis rate over 24h 
and DXA was used for lean and fat body mass.  
 
This study had a different study design from the other studies that primarily examined free 
living patients. The study convincingly demonstrated that EAA ameliorate muscle loss 
without affecting satiety even when in forced inactivity. Intervention period was only 10 days 
but should reflect a typical hospitalization. 
 
Dal Negro et al 2010 
The aim of this study was to examine if 8g of EAA supplementation compared to placebo in 
chronic obstructive pulmonary disease (COPD) patients could improve body composition, 
muscle metabolism, physical activity, cognitive function, and health status. COPD is a 
common condition and often associated with weight loss. The study is an RCT with a double 
blind protocol. 32 out-patients (25 males) were randomized into two groups, 16 each. One 
received 4g EAA and the other a placebo. Measures were done at baseline, after 4 weeks and 
at the end which was 12 weeks. Muscles mass was evaluated using BIA.   
 
The EAA supplemented group improved in all measured outcome variables compared to the 
placebo group. Most impressive was the 6 kg weight increase, were 3.6 kg of this was 
measured as fat free mass increase.  
 
Subjects in this study were diagnosed with sarcopenia as well as COPD. Their high catabolic 
state compared to many subjects in the other studies is most likely the reason for the high 
positive results. 
 
Dal Negro et al 2012 
This study is similar to the previous one with the same main author. The aim of this study was 
to evaluate 8g EAA compared to placebo in 88 COPD out-patients with a BMI < 23. Subjects 
were randomized to receive placebo (n=44) or EAAs (n=44) for 12 weeks, it was a non-
blinded RCT. Subjects were not formally diagnosed with sarcopenia but had many of the 
characteristics of the diagnosis, such as low muscle mass. Primary outcome measures were 
changes in both physical activities in daily life and quality of life. Measurements were done 
using questionnaires and “Sense wear armbands”. They measured muscle function with hand 
dynamometers, walking speed and muscle mass using BIA which is reported in table 3. There 
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was a positive effect on muscle mass in both groups but only the EAA supplemented group 
increased muscle function, measured as steps per day and hand grip strength.  
 
Kyung Kim et al 2012 
The aim of this study was to use a RCT protocol and evaluate the effect of four different 
methods for increasing strength and muscle mass in community dwelling Japanese elderly (75 
years and older) women. The four different interventions were 6g EAA supplementation, 
exercise, exercise + 6g EAA and only health education. Out of 155 women enrolled into the 
study 144 completed the three month intervention. The conclusion was that EAA + exercise 
was the best for increasing strength and muscle mass. Compared to only health education the 
EAA group showed more significant improvements. So EAA in itself without exercise was 
beneficial for these sarcopenic women.   
 
This study differed somewhat from the others in having four different intervention groups. 
When trying to compare these results with the other studies the EAA group was treated as the 
intervention group and the health education group was considered the placebo group.   
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Table 2. Study descriptions  
Author, year Study Design Intervention n Subjects Subject status Mean age years BMI 
Scognamiglio et al 
2005 
Blinded RCT 
Duration: 12 weeks 
AA mixture (All 
EAA + tyrosine and 
cystine) 12 g/day 
 
12 weeks 
95 subjects 
42 male  
53 female 
Subjects not 
complicated with 
sarcopenia, 
otherwise healthy 
elderly subjects 
with reduced 
physical activity 
I = 74  
P = 74 ± 5 
I =  27.4 ± 3.6  
P = 27.3 ± 3.7 
Børsheim et al 
2008 
Clinical trial, one 
intervention group 
Duration: 16 weeks 
10 g of EAA + 1.1g 
arginine two times 
a day (total 22 g 
EAA in a day) 
 
16 weeks  
12 subjects  
5 male 
7 female 
Subjects not 
complicated with 
sarcopenia, defined 
as elderly impaired 
glucose tolerant 
subjects 
67 ± 5.6  Non given, but 
weight was 74.3 ± 
19.7 kg 
Solerte et al 2008 A randomized, 
open-label, 
crossover study 
Duration: 48 weeks 
of supplementation 
16 g/day of EAA 
 
78 weeks  
41, no information 
about gender 
Elderly subjects 
complicated with 
sarcopenia and  
reduced whole-body 
lean mass  
No mean age given, 
Age span was 66–
84 
19 - 23 
Dillon et al 2009 Double blind RCT 
Duration: 12 weeks 
15 g/day EAA 
 
12 weeks 
14 female subjects Subjects not 
complicated with 
sarcopenia, 
otherwise healthy 
living independently 
at home 
I = 67 ± 1  
P = 69 ± 3 
I =  26.8  
P =  26.7 
Ferrando et al 
2009 
Non blinded RCT 
Duration: 10 days 
of bed rest 
15 g EAA three 
times a day (total 
45 g EE a day) 
 
10 days 
22 subjects 
7 male 
15 female 
Healthy elderly 
subjects, subjected 
to a 10 day bed 
rest protocol 
I = 71 ± 6 
P = 68 ± 5 
Non given, but 
weight was in P = 
83 ± 19 kg and I = 
72 ± 8 kg 
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Author, year Study Design Intervention n Subjects Subject status Mean age years BMI 
Dal Negro et al 
2010 
Double blind RCT 
Duration: 12 weeks 
4 g EAA two times a 
day (total 8 g EAA 
a day) 
 
12 weeks 
32 subjects  
25 male  
7 female 
 
Subjects 
complicated with 
sarcopenia 
suffering from 
chronic obstructive 
pulmonary disease 
I =  75 ± 7  
P = 75 ± 7 
I = 20.2 ± 1.4  
P = 20.2 ± 1.8 
Dal  Negro et al 
2012 
Non blinded RCT 
Duration: 12 weeks 
4 g EAA two times a 
day (total 8 g EAA 
a day) 
 
12 weeks  
88 subjects 
61 male  
27 female 
Outpatients with 
stable, severe 
COPD 
I = 75 ± 5 
P = 73 ± 8 
I = 19.95 ± 1.63 
P = 20.1 ± 2 
Kyung Kim et al 
2012 
Non blinded RCT 
Duration: 3 months. 
3 g Leu rich EAA 
two times a day 
(total 6 g EAA a 
day) 
 
12 weeks 
150 subjects, all 
female. Assigned to 
4 different groups. 
N = 37 in the EAA 
group.  
Free living, defined 
as sarcopenic 
75 years and older < 22 
I = Intervention group. 
P = Placebo group. 
n = Number of subjects. 
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Intervention results 
 
The results in selected and relevant measurements are displayed in two tables. Table 3 
displays baseline value, end value and its % change.  
 
 
Table 3. Results after intervention compared to baseline in accordance to selected 
endpoints.  
Author, year Endpoint Baseline End % change 
Scognamiglio et 
al 2005 
MIMS right hand, 
kg 
Week 0: 
I: 14.6 ± 2.2 
P: 14.4 ± 2.4 
Week 12: 
I: 20.2 ± 2.0 
P: 14.0 ± 2.8 
 
I: + 38.3 % 
P: - 2.8 % 
 6-min walking 
distance, m 
Week 0: 
I: 212.5 ± 34 
P: 212.0 ± 36 
Week 12: 
I: 268.8 ± 34.9 
P: 212.0 ± 40 
 
I: + 26.5 % 
P: ± 0 % 
Børsheim et al 
2008 
Lean body mass, 
kg 
Week 0: 
47.97 ± 3.0 
Week 16: 
48.57 ± 3.0    
 
I: + 1.3 % 
 Lean leg mass, kg Week 0: 
14.98 ± 1.0 
Week 16: 
15.31 ± 1.08 
 
I: + 2.2 % 
 Leg 1 repetition 
max 
Week 0: 
127.5 ± 21.8 
Week 16: 
145.6 ± 19.2 
 
I: + 14.2 % 
 Walking speed 
m/s 
Week 0: 
1.26 ± 0.05 
Week 16: 
1.34 ± 0.05 
 
I: + 6.3 % 
Solerte et al 2008 Lean body mass, 
kg 
Week 0: 
I1: 47.5 
I2: 46.5 
Week 78: 
I1: 50.0 
I2: 49.0 
 
I1: + 5.3 % 
I2: + 5.4 % 
Dillon et al 2009 Lean body mass, 
kg 
Week 0: 
I: 43.5 ± 2.8 
P: 40.7 ± 2.4 
Week 12: 
I: 45.2 ± 3.0 
P: 41.0 ± 2.8 
 
I: + 3.9 % 
P: + 0.7 % 
 Upper/lower body  
Strength tests 
Week 0: 
NS 
Week 12: 
NS 
 
- 
Ferrando et al 
2009 
Lean body mass, 
kg 
Day 0:  
I: 43.0 ± 0.2 
P: 46,8 ± 0.3 
Day 10: 
I: 42.1 ± 0.2 
P: 45.3 ± 0.3 
 
I: - 2.1 % 
P: - 3.2 % 
 Stair ascent power 
(Nm/s) 
Day 0: 
I: 293.5 ± 37.2 
P: 407.2 ± 69.9
 
Day 10: 
I: 284.2 ± 43.0 
P: 336.5 ± 47.6
 
 
I: - 3.2 % 
P: - 17.4 % 
 Standing plantar 
flexion (rep/30 s) 
Day 0: 
I: 21.8 ± 1.4 
P: 21.8 ± 3.4 
Day 10: 
I: 21.4 ± 2.5 
P: 20.9 ± 2.8 
 
I: - 1.4 % 
P: - 4.1 %  
Dal Negro et al 
2010 
Lean body mass, 
kg 
Week 0: 
I: 40.4 ± 4.0 
P: 39.9 ± 4.8 
Week 12: 
I: 44.0 ± 4.5 
P: 39.7 ± 2.8 
 
I: + 8.9 % 
P: - 0.5 % 
 Steps per day Week 0: 
I: 638.8 ± 661.8 
P: 609.8 ± 454.7 
Week 12: 
I: 1140.5 ± 524.4 
P: 562.9 ± 601.9    
 
I: + 78.5 % 
P: - 7.7 % 
Dal  Negro et al 
2012 
Lean body mass, 
kg 
Week 0: 
I: 40.2 ± 4.23 
P: 35.80 ± 5 
Week 12:  
I: 43.86 ± 4.76 
P: 39.6 ± 2.5 
 
I: + 9.1 % 
P: + 10.6 % 
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 MIMS right hand, 
kg 
Week 0: 
I: 21.6 ± 1.36 
P: 22.1 ± 1.9 
Week 12: 
I: 23.2 ± 1.6 
P: 21.5 ± 1.7 
 
I: + 7.4 % 
P: - 2.7 % 
 Steps per day Week 0: 
I: 638.68 ± 662.1 
P: 609.70 ± 454.8 
Week 12: 
I: 1140.33 ± 524 
P: 562.77 ± 601.9 
 
I: + 78.7 % 
P: - 7.7 % 
Kyung Kim et al 
2012 
Lean body mass, 
kg 
Month 0: 
I: 26.25 ± 1.81 
P: 27.48 ± 2.04 
Month 3:  
I: 26.53 ± 2.10 
P: 27.66 ± 2.23 
 
I: + 1.0 % 
P: + 0.6 % 
 Maximum 
walking 
speed, m/s 
Month 0: 
I: 1.71 ± 0.28  
P: 1.57 ± 0.31 
Month 3: 
I: 1.92 ± 0.27 
P: 1.64 ± 0.31 
 
I: + 12.3 % 
P: + 4.5 % 
 Knee extension 
strength, Nm/kg 
Month 0: 
I: 1.15 ± 0.25 
P: 1.14 ± 0.26 
Month 3: 
I: 1.14 ± 0.25 
P: 1.00 ± 0.26 
 
I: - 0.9 % 
P: - 12.3 % 
 
I = Intervention group. 
P = Placebo/control group.  
NS = No significant difference so data wasn’t further reported. 
MIMS = maximal isometric muscle strength (handgrip dynamometer) 
 
Study quality according to GRADE 
 
Table 4. Study quality according to GRADE 
Author, year Study quality according to GRADE 
Scognamiglio et al 2005 Moderate 
Børsheim et al 2008 Moderate 
Solerte et al 2008 Low 
Dillon et al 2009 High 
Ferrando et al 2009 Moderate 
Dal Negro et al 2010 High 
Dal  Negro et al 2012 High 
Kyung Kim et al 2012 Moderate 
 
 
Evidence strength of effect: 
 
Lean body mass: Moderate (+++) 
Muscle Strength/function: High (++++) 
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Discussion 
 
Summary of evidence 
 
Even though the eight different intervention studies included in this systematic review were 
mutually different in study quality, dosage and length of the intervention they all showed a 
significant positive effect of EAA on selected outcome variables compared to placebo or at 
baseline. Studies included a total of 454 subjects. Which was often sufficient to get a 
statistical significant result? Still it’s a limited number of subjects to generalize the positive 
results to a wider diverse population of older adults.    
 
Dose EAA given varied between 6.7 – 45g/day (mean 15g). The study which spanned 16 
weeks and with a dose of EAA in the higher span, 22g (40) did not show greater effect on 
outcome variables than those with lower dose, between 8 - 15 g (LBM only + 1,3% ). The 
dose-response in the analyzed studies is not linear. 22g EAA a day does not seem to be more 
efficient then 8-15g a day. The most efficient dosage is therefore hard to determine based on 
present results. There have been attempts to determine the optimal AA dose for protein 
synthesis in elderly but it has proven methodologically difficult since it’s both hard to 
measure reliable and apply pre-clinical laboratory results to a clinical realistic setting. Studies 
on muscle protein synthesis often use young men as test subjects which is far from 
representative of elderly sarcopenic individuals (48). Further research on optimal dosage for 
sarcopenic individuals is needed but supplementation with 15g EAA daily seems a warranted 
dosage to aim for based on the present scientific material. 
 
The duration of intervention varied between studies even though the majority of studies were 
12 weeks and seem it could be representative for a longer period of impaired mobilization. 
Long term follow after supplementation was discontinued is also up is missing. It is therefore 
not possible to say anything about the long term effect of the intervention. Having a positive 
effect during this short but critical period should theoretically be sufficient to maintain 
enough muscle mass and function to again being able to be self-sufficient in activities of daily 
life (ADL).  
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When examining individual EAA for further optimization of the supplement, Leu seem to be 
the EAA which have the most positive effect on protein synthesis and alone has been 
suggested as a so called pharmaconutrient to prevent and treat sarcopenia (49). Leu 
metabolizes in the body to the active metabolite Beta-hydroxy-beta-methylbutyrate (HMB) 
which compared to a energetically equivalent dose Leu further stimulate muscle protein 
synthesis trough the mTOR–p70S6K1 pathway (50). Therefore there are expectations that 
HMB  is an even more energetically efficient promoter of muscle synthesis than AA or EAA. 
This was evalutated in a recent study (51). This study had 19 subjects confined to a complete 
bed rest for ten days and followed by eight weeks of resistance training. One group was 
randomized to receive 1,5g HMB twice daily starting five days before the bed rest and ended 
at the end of the exercise period. The control group got a placebo powder. DXA was used to 
evaluate body composition. There was a significant difference in preservation of muscle mass, 
but difference in muscle function could not be observed between groups. Authors concluded 
sample size was probably too small to show effect on muscle function, with a larger sample 
size they theorize an effect probably would be observed (51). These results are early and 
experimental but are however promising for further investigation.  
 
Physiological changes occurring during aging are factors that need to be considered according 
to evaluating optimal dosage and timing for supplementation with EAA. Changes such at that 
AA transporters gets up regulated differently in muscle in young compared to old men after 
resistance exercise and AA ingestion (15). There is also indications that elderly have a 
diminished muscle accretion of muscle protein when ingesting a bolus EEA compared to 
young individuals (16). The muscle tissue itself seems to change when aging. Muscle size and 
muscle strength are not proportional throughout life (5). This can be explained by how many 
connections and how effective they are. It has been shown that nerve conduction is slower and 
that connections are not as numerous and effective for elderly < 65 years as in younger 
individuals. A term that some use of for this phenomenon is dynapenia, referring to these 
impaired neuromuscular connections (52). Again showing that activation of muscles 
throughout life can also maintain this neuromuscular connection regardless of LBM and that 
future studies on protein synthesis, function and EEA needs to be done on elderly test 
subjects.  
 
Resistance training as mentioned in the introduction has shown to be beneficial for muscle 
function and syntheses in older adults (23, 24). Since disease and disability is more frequent 
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in the elderly population, resistance training is not always an alternative. Frequent episodes of 
physical inactivity (and inflammation) such as hospital stays could also make resistance 
training and ADL hard to maintain. Therefore nutritional supplement strategies for periods of 
forced inactivity are still needed. Still when it is possible, nutrition together with resistance 
training are in most cases complementary treatment strategies that has shown a synergistic 
anabolic effect (23).. 
 
Still many questions remain unsolved according to optimal intake of EAA, other AA, HMB 
and dietary protein intake in elderly sarcopenic individuals for maintenance of muscle mass 
and function. Question such as what is an optimal dosage for maximum muscle protein 
synthesis? Should supplementation be administered as a bolus dose or spread out? Should a 
combination of EAA be used? Should other micronutrients mentioned earlier in the review be 
added? To hopefully resolve some of these questions a large RCT should be performed on 
elderly geriatric subjects defined as sarcopenic. Suggesting, intervention for at least 16 weeks 
comparing different interventions such as only EAA and combinations with other suggested 
micronutrients such as omega-3 and HMB, compared with placebo. The test subjects should 
have the sarcopenia diagnosis defined in the “European consensus report” (1) is 
recommended to be used. All subjects should have a follow up on the pre-defined endpoints a 
few months after supplementation is discontinued to see if the potential difference in 
outcomes persist and actually effect individuals health and quality of life. The reasoning being 
that if EAA supplementation can maintain or increase a certain level of LBM this could keep 
the individuals active enough to keep their strength and function and not deteriorate further. 
Even a short period of impaired mobilization in the elderly can be enough to lead to a 
permanent impaired physical function and lack of autonomy.  
 
Sarcopenia as well as other forms of malnutrition is generally underdiagnosed, and needs to 
be recognized to get more attendance in the healthcare system (3). If the condition is not 
systematically diagnosed, appropriate interventions to treat and ameliorate sarcopenia will be 
difficult. Currently there is a lack of treatment options besides physical therapy which is not 
possible for everyone. So when treatments, such as perhaps EAA or similar dietary 
supplementation interventions become more available and established clinicians might be 
more aware and prone to properly diagnose and treat sarcopenia when they also have 
treatment options.  
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Limitations 
 
Systematic reviews have their methodological limitations, further reviewed in (53). Some of 
these limitations include that inclusion and exclusion criteria are pre-defined, by the author. 
The selection of inclusion/exclusion criteria can lead to inclusion-bias. For example choosing 
a certain cut-off age on the subjects that might affect the intervention effect.  It is important to 
consider that criterias often are selected based on the author’s current knowledge of the field 
reviewed. The risk of publication bias also needs to be considered, studies that yield positive 
results tend to be published more often than those presenting negative results. The selection of 
studies will therefore not be a random sample from the literature. The analysis of each study 
is also performed by one or a few persons and even though standardized forms were used to 
grade the studies there is a risk of some subjectivity.  
 
A further limitation with the present systematic review is the current lack of a worldwide 
consensus on the definition of sarcopenia. Even though there is some overlap of the 
definitions on the subjects included in the studies and they all fit the inclusion and exclusion 
criteria they were slightly different in study population, length of intervention (10 days to 48 
weeks, 12 weeks were used in five out of eight studies), with no long term follow up and 
dosage of EAA used (6.7 – 45g/day, mean 15g). The subjects in the studies were all above 65 
years of age but some of their baseline values considering muscle mass and comorbidities 
differed. Only the population in three of the eight studies was officially diagnosed with 
sarcopenia. But the others resembled the sarcopenic definition, with low LBM, low strength 
and having low SPBB. Still the lack of consistence both with regard to the criteria for 
inclusions, methods for evaluating effect, type of EAA supplementation, dosage and time for 
administration together constitutes the main limitation in applying the results to a wider 
clinical practice.  
 
Conclusions and implication 
 
To summarize results from the eight heterogenic studies all showed effect of EAA 
supplementation either for maintaining or increasing LBM, strength and function. It seems 
that the more frail subjects also gained the best clinical effect. It supports the theory that the 
more untrained muscle also gain the best effect from strength training. The conclusion is 
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therefore that short term supplementation with EAA to individuals over 65 years of age and 
with or at risk of sarcopenia is beneficial both for ameliorating/gaining muscle mass and 
strength/function. Based on current research there is potential for clinical use of EAA 
supplementation in the future. Theoretically, based on present studies it seems to be most 
effective in the short term, for example to administer EAA supplement during and a few 
weeks after the hospital stay, as the long term effect of continued supplementation is not yet 
studied. So still many questions remain regarding mechanisms, optimal EAA, dose and 
duration of therapy. 
 
Another aspect when prescribing supplementations to older adults is the frequent prevalence 
of polypharmacy. Therefore adding more tablets would perhaps be too demanding resulting in 
low compliance to prescribed medications/treatments. Instead other forms of EAA 
administration could be considered. EAA fortified sip-feeds or other forms of EAA liquid 
fortification or food fortification would also be possible. An advantage with sip feed is that 
they also contain energy and other nutrients. However, compliance to sip feed may also vary 
considerably. A problem with food fortification is that if done improperly it will negatively 
affect sensory aspects and therefore affect compliance since many elderly show impaired 
appetite and altered or lowered taste and smell perception (54). In summary prescription of 
EAA must be made not only with regard to individual needs but also considering the specific 
conditions and preferences of the individual patient for good compliance.  
 
Sarcopenia as a nutrition related disorder also needs to be clearly defined, both for research 
purpose and clinical work.  One could argue that it is a natural consequence of aging but the 
multifactorial etiology and individual variations in its progression warrants further research 
into the pathophysiology and potential treatments such as EAA supplementation. New 
knowledge within these fields may open up for innovative new treatment strategies and 
targeting mechanisms to ameliorate or reverse progression associated with the sarcopenic 
syndrome.   
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Populärvetenskaplig sammanfattning 
 
Förlust av muskelmassa, styrka och funktion är vanligt förekommande bland äldre. 
Förekomsten ökar med stigande ålder och sambandet med sjukdom är starkt. Fysisk 
inaktivitet, i synnerhet ofrivillig inaktivitet som att vara sängliggande under en sjukhusvistelse 
bidrar till förlusten. Detta fenomen benämns ofta i litteraturen som ”sarkopeni”. Orsakerna till 
sarkopeniutvecklingen är flera, men fysiologiska förändringar relaterad till hög ålder anses 
vara den främsta orsaken om ingen annan specifik anledning kan hittas. Hur sarkopeni ska 
beskrivas och diagnosticeras finns publicerat (1).  
 
I denna systematiska litteraturöversikt sammanställs åtta studier som studerat effekten av en 
extra tillförsel essentiella (livsnödvändiga) aminosyror till individer över 65 år. Man har för 
att utvärdera effekten mätt muskelmassa och muskelstyrka/funktion. Studierna skilde sig 
något åt avseende doser av essentiella aminosyror och tiden för behandling, men man gav i 
medel 15g och de flesta studier pågick 12 veckor. Samtliga studier bedömdes som relevanta 
för att kunna besvara den aktuella frågeställningen. 
 
Eftersom behovet av fördjupad kunskap om sarkopeni och lindrande behandlingar vid detta 
tillstånd är stort är litteraturöversikter som denna viktiga för att summera den kunskap som 
finns.  
 
Slutsatsen är att tillskott av essentiella aminosyror till äldre över 65 år som är diagnostiserade 
med sarkopeni eller i riskzonen för att utveckla detta tillstånd ger en positiv effekt på 
muskelmassa styrka och funktion. Essentiella aminosyror stimulerar uppbyggnad av 
muskelprotein betydligt mer än motsvarande mängd energi genom andra proteinkällor.  
 
Mer forskning inom området behövs dock för att kunna använda tillskottet praktiskt i klinisk 
vardag. 
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Appendix: Review templates 
 
Review template 1. 
Granskningsmall för randomiserad kontrollerad prövning – modifierad 
från SBU mall  
Författare, år alternativt SBU:s identifikationsnummer: 
      
Anvisningar: 
 Alternativet ”oklart” används när uppgiften inte går att få fram från texten 
 Alternativet ”ej tillämpligt” väljs när frågan inte är relevant. 
 Det finns förtydligande kommentarer till vissa delfrågor. Dessa anges med en fotnot. 
 
 Ja Nej Oklart Ej tillämpligt 
Extern validitet - (Directness) 
1. Studiepopulation 
a) Framgår det hur många personer som exkluderades före 
randomiseringen?     
b) Är redovisningen av personer som inte randomiserades, 
trots att de var valbara, adekvat?     
     
     
e) 
     
f) 
     
Intern validitet  (Risk of bias – Study limitations)  
2. Tilldelning av åtgärd/intervention/behandling 
a) Användes en randomiseringsmetod som på ett 
acceptabelt sätt minimerar risken för manipulation?     
b) Utfördes randomiseringen så att fördelningen  
blev oförutsägbar och slumpmässig? 1     
c) Påbörjade samtliga deltagare, som randomiserades, 
behandlingen? 2     
3. Gruppernas jämförbarhet 
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 Ja Nej Oklart Ej tillämpligt 
a) Var grupperna vid baseline rimligt lika avseende 
egenskaper som kan påverka resultatet  
(t ex ålder, kön, sjukdoms svårighetsgrad)? 
    
4. Blindning (maskering) 
3 
Blindades följande på tillfredsställande sätt: 
a) Patienter     
b) Prövare/behandlare     
c) Utvärderare av resultat     
 
5.Studielängd  
    
     
 
 Ja Nej Oklart Ej tillämpligt 
6. Bortfall (antalet randomiserade deltagare som inte har följts upp enligt studieprotokollet) 
4 
a) Går det att följa deltagarnas väg genom studien  
t ex i ett flödesschema?     
b) Är storleken på bortfallet efter randomisering acceptabelt?     
c) Är orsakerna till bortfallet acceptabla?     
7. Följsamhet (”compliance, adherence, concordance”) 
5 
a) Framgår det i vilken utsträckning deltagarna fullföljde 
behandlingen?     
b) Var andelen som fullföljde behandlingen acceptabel?     
8. Rapportering av effektmått och biverkningar 
a) Var det primära effektmåttet definierat i förväg och 
adekvat rapporterat?     
b) Var de sekundära effektmåtten definierade i förväg och 
adekvat rapporterade?     
c) Baserades slutsatserna på enbart i förväg definierade 
effektmått och subgruppsanalyser? 6     
d) Har utfallen av samtliga viktiga effektmått redovisats  
på ett adekvat sätt? 7     
e) Rapporterades biverkningar/komplikationer på ett 
tillfredsställande sätt?     
 
Precision 
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a) Redovisas resultaten på ett adekvat sätt? 8     
b) Har resultaten beräknats med lämplig analysmetod? 9     
c) Var den minsta kliniskt relevanta effekten definierad på 
förhand?     
d) Är den valda minsta kliniskt relevanta effekten av rimlig 
storlek?     
e) Har man använt acceptabla metoder för att mäta 
effekterna?     
f) Mättes observatörsöverensstämmelsen på ett acceptabelt 
sätt? 10     
g) Är de överväganden och beräkningar som ligger till grund 
för antal deltagare acceptabla (”power”-analys)? 11     
 
Bindningar och jäv 
a) Anges eventuella bindningar och jäv (”declaration of 
interest ”)?     
b) Bedömer du att studiens resultat inte påverkats  
av intressekonflikter?     
 
Review template 2. 
Granskningsmall för kohortstudier med kontrollgrupp – modifierad från 
SBU mall 
Författare, år alternativt SBU:s identifikationsnummer: 
      
Anvisningar: 
 Alternativet ”oklart” används när uppgiften inte går att få fram från texten. 
 Alternativet ”ej tillämpligt” väljs när frågan inte är relevant. 
 Det finns förtydligande kommentarer till vissa delfrågor. Dessa anges med en fotnot. 
 
 Ja Nej Oklart Ej tillämpligt 
Extern validitet  (Directness) 
1. Jämförbarhet 
a) Är kontrollgruppen eller grupperna adekvat valda? 1     
b) Är det en kliniskt relevant kontrollgrupp?     
c) Är det sannolikt att interventions- och 
kontrollgruppen valdes ut och diagnostiserades på ett 
likartat sätt? 2 
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Intern validitet (Risk of bias – Study limitations) 
2.1. Förväxlingsfaktorer (”confounders”) 
a) Har författarna identifierat alla viktiga 
förväxlingsfaktorer och tagit hänsyn till dem i 
analyserna? 3 
    
b) Var skillnaderna mellan grupperna i baslinjedata 
små? 3     
c) Är risken för selektions- eller indikationsbias liten? 4     
2.1. Följsamhet, bortfall 
2.1.1 Följsamhet (”compliance, adherence”) 
a) Framgår det i vilken utsträckning deltagarna 
fullföljde behandling?     
b) Var andelen som fullföljde behandlingen acceptabel?     
2.1.2 Bortfall (antalet deltagare som inte har följts upp enligt studieprotokollet) 
a) Redovisas hur stort bortfallet är? 5     
b) Anges orsakerna till bortfallet? 5     
c) Är bortfallet acceptabelt? 5     
3. Blindning 
Var de som bedömde utfallen omedvetna om 
deltagare tillhörde interventions- eller 
kontrollgruppen? 6 
    
4. Analys 
a) Har den statistiska analysen av osäkerhet hanterats 
på ett adekvat sätt? 8     
b) Försökte författarna statistiskt korrigera för 
obalanser mellan grupperna med avseende på 
förväxlingsfaktorer/”confounders”? 9 
    
5. Biverkningar 
Mättes biverkningar/komplikationer på ett 
tillfredsställande sätt?     
 
Precision 
a) Är de överväganden och beräkningar som ligger till 
grund för urvalsstorleken (”sample size”) tydligt 
beskrivna? 7 
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b) Är den statistiska styrkan (”power”)  tillfredsställande 
hög? 7     
 
Bindningar och jäv 
a) Finns en förteckning över eventuella bindningar och 
jäv (”declaration of interest”)?     
b) Bedömer du att studiens resultat inte påverkats  
av intressekonflikter?     
 
 
 
Review template 3 
Work sheet –Certainty of evidence (GRADE) 
 
 
Disease/ disorder: 
 
Intervention/ method vs. control: 
 
Outcome variable: 
 
Included studies    RCT, No…….     SR, No…………   Cohort studies, No……….  
 
Number of patients: 
 
 
Assessment of risk of bias (“internal validity”)   Assessment of
 “external 
validity”  
      and precision  
Study 
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+ = low risk/good         ? = unclear risk           = high 
risk/bad 
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Study limitations  
(Randomisation, blinding, follow-up, drop-out/withdrawals, intention-to-
treat) 
 
 Mark with cross-
sign 
 
No serious limitations 0  
Some limitations (but not enough to downgrade)) 0?  
Serious limitations (downgrade one step) -1  
Very serious limitations (downgrade two steps) -2  
Comment limitations or reasons to downgrade: 
 
 
 
 
Consistency 
(Estimate of relative effect, same magnitude and direction across studies? 
overlapping confidence intervals?) 
 
Mark with cross-
sign  
 Based on meta-analysis? Statistical analysis of heterogeneity:  Chi2        
 I 2 
  
No serious inconsistency 0  
Some inconsistency (but not enough to downgrade) 0?  
Serious inconsistency (downgrade one step) -1  
Very serious inconsistency (downgrade two steps) -2  
Comment limitations or reasons to downgrade: 
 
 
 
 
Directness  
(study population – external validity, specificity of intervention, relevance 
of the comparator to the intervention, clinical setting, adequate time of 
follow-up) 
 
Mark with cross-
sign  
No uncertainty  0  
Some uncertainty (but not enough to downgrade) 0?  
Serious indirectness (downgrade one step) -1  
Very serious indirectness (downgrade two steps) -2  
Comment limitations or reasons to downgrade: 
 
 
 
Precision 
(Few events, wide confidence intervals that also include possible 
unfavourable effects) 
 
Mark with cross-
sign  
No imprecision 0  
Uncertain precision (but not enough to downgrade) 0?  
Serious imprecision (downgrade one step) -1  
Very serious imprecision (downgrade two steps) -2  
Comment limitations or reasons to downgrade: 
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Publication bias  
(Few and small studies from one research group or company which all 
show the same type of results, well.known unpublished studies) 
 
Mark with cross-
sign  
Unlikely 0  
Uncertainty (but not enough to downgrade) 0?  
Likely (downgrade one step) -1  
Very likely (downgrade two steps ) -2  
Comment limitations or reasons to downgrade: 
 
 
 
Magnitude of effect Mark with cross-
sign 
 
Not relevant 0  
Large effect (RR<0,5 or >2)  (upgrade one step) +1  
Very large effect (RR<0,2 or >5)  (upgrade two steps) +2  
Comment limitations or reasons to downgrade: 
 
 
 
Comments on other important aspects of the level of evidence (clear dose-response gradient that 
may allow upgrading?, confounders that clearly reduce the magnitude of the effect?) 
 
 
 
Is the sum of uncertainties (?) enough to motivate downgrading with one 
step? 
Mark with cross-
sign 
Yes  - 1  
No  0  
 
 
Certainty of evidence Mark with plus-
signs 
  
High   
Moderate    
Low    
Very low   
 
 
Namn. Datum: 
 
